Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
While Trump spent much of his nearly two-hour speech in Michigan ’s Grand Rapids hurling insults and profanities at his ...
María Camila Zarta tells TODAY.com that as a Colombian immigrant seeing the singer felt like he gave her a piece of her ...
1d
Ashby Kilgore was a bit apprehensive when she retired after 46 years in the public school system. “It was like, ‘What the ...
Martha Stewart is not big on sharing her feelings. To the millions who greedily gobbled up scuttlebutt about her legendary ...
Read on for updates about Heidi Klum's 2024 Halloween party including what she wore and other guests wore. Here are photos of ...
Stocktwits on MSN15h
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 PerformanceHims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback